Search for Merck KGaA and
    1. September 22, 2014

      Merck KGaA: Adrenalin shot

      Most big deals leave the buyer’s stock sluggish. Merck KGaA’s decision to buy Sigma-Aldrich for $17bn hit like an adrenalin...

    2. September 22, 2014

      Merck to buy US’s Sigma-Aldrich for $17bn

      Germany’s Merck KGaA has agreed to pay $17bn for Sigma-Aldrich of the US in a deal that will sharpen its focus on speciality...

    1. August 17, 2014

      Lanxess buoyed by Zachert’s return to take helm of group

      When Matthias Zachert announced in January that he would step down from his role as chief financial officer at Merck KGaA...

    2. May 7, 2014

      Lanxess to raise 10% more capital

      Lanxess is set to issue new shares equivalent to 10 per cent of its equity capital as new chief executive Matthias Zachert...

    3. February 9, 2014

      German drugmaker Merck steps up push into biosimilars

      Merck is stepping up its push into a new class of copycat medicines that offer hope of lower drugs bills for national...

    4. January 27, 2014

      Merck: teary farewell

      Chief financial officers are supposed to sweet-talk markets. That is their job. But is sweet talk worth a 10th of a...

    5. January 26, 2014

      Lanxess chief Heitmann to quit as profits fall

      Lanxess chief executive Axel Heitmann is to stand down after the speciality chemical company’s profits were hit by growing...

    6. December 6, 2013

      Letter from Lex: giving up investor fight

      Activist investors get a bad rap. Sometimes they deserve it, such as when famed US corporate raider Carl Icahn first stood...

    7. December 5, 2013

      Lynch backing augments the prospects for Neurence

      It is James Bond meets Harry Potter meets Arnie Schwarzenegger. And Mike Lynch meets them all. Don the glasses or point your...

    8. December 5, 2013

      Merck KGaA: chemical weapon

      Diversification, thy name is Merck. Since 2007, the German chemical and pharmaceutical group has been on a transformation...

    9. September 30, 2013

      Investors should seek to add ratios to new pay regime

      The friction between Tories and Liberal Democrats through the political conference season makes the harmony on display in...

    10. August 6, 2013

      Merck KGaA: drug screening

      Merck KGaA, as its corporate history says, has been offering “growth and transformation since 1668”. Even after 345 years,...

    11. July 28, 2013

      Loescher’s Siemens tenure looks tenuous

      When Peter Loescher was hired from Merck, the pharmaceuticals group, in 2007, the new Siemens chief executive moved...

    12. June 19, 2013

      Lundbeck fined €94m for ‘pay for delay’ deals to rivals

      European regulators have fined Lundbeck, the Danish pharmaceutical company, €94m for paying rivals to delay cut-price...

    13. May 28, 2013

      Pharma M&A: defensive deals

      Another day, another healthcare sector deal. AstraZeneca’s purchase of Omthera on Tuesday is small (maximum value: $443m),...

    14. May 22, 2013

      Metro rises after broker gets positive

      Metro was in high demand after the German retailer received a vote of confidence from Morgan Stanley analysts for the first...

    15. May 9, 2013

      Germany: for richer, for poorer

      Pity the poor Germans. Never mind that two Bundesliga teams are in the Champions League football final this month. Or that...

    16. March 11, 2013

      Skills for global business

      When Doug Baillie first walked into his Mumbai office as the chief executive of Hindustan Lever in 2006, he knew he would be...

    17. February 11, 2013

      Novo Nordisk ails after drug ruling

      News that Novo Nordisk , the Danish drugs company, failed to win approval for a new drug triggered a strong response from...

    18. December 6, 2012

      Contrasting fortunes for Germany and Italy

      German stocks hit a near five-year closing high on Thursday, while Italian stocks fell amid domestic political tensions, in...

    19. December 6, 2012

      Frankfurt stocks near 4-year high

      German stocks were edging up towards multiyear highs on Thursday, while Italian stocks fell sharply amid domestic political...

    20. November 28, 2012

      Outsourced drug trials lack oversight, study says

      Leading pharmaceuticals companies show no evidence that they adequately supervise the conduct of outsourced clinical drug...

    21. November 4, 2012

      Pharmas offer to cap cost of Greek medicine

      Leading pharmaceutical companies have offered to cap the total costs of medicines supplied to the Greek government, as they...

    22. November 3, 2012

      Merck halts cancer drug supply to Greek hospitals

      FRANKFURT, November 3 – Merck, the German pharmaceuticals group, is no longer delivering the cancer drug Erbitux to Greek...

    23. August 26, 2012

      Belt-tightening reaches heart of Germany

      Cost cutting and job losses are no longer confined to Europe’s indebted periphery. As the eurozone heads towards another...

    24. March 28, 2012

      Bertelsmann: going forward ... at last

      No offence to Gütersloh, but Bertelsmann looks ready to shed its small-town mentality. Chief executive Thomas Rabe has...

    25. March 28, 2012

      Bertelsmann moves closer to stake sale

      Bertelsmann has taken a step towards selling a strategic stake, or listing its shares on the stock market, moves that would...

    26. March 5, 2012

      European drugmakers

      Developing drugs can be all or nothing. To see how the sharp edge of that proposition feels, look at UCB and Merck. During...

    27. February 15, 2012

      European healthcare: Ailments encapsulated

      In the European Commission’s enterprise directorate in Brussels, offices have emptied in recent months as officials who once...

    28. February 5, 2012

      Pharma seeks to ease pain of euro crisis

      With Greece and Spain struggling to repay billions of euros in outstanding debts to the healthcare sector as the eurozone...

    29. December 30, 2011

      European banks suffer as crisis grows

      European equity markets had a largely unremarkable last week of 2011, but few investors were likely to forget this year,...

    30. December 5, 2011

      A model for healthier profits

      When Poul Rasmussen is asked to justify the unusual governance structure of Leo Pharma, the Danish pharmaceutical group, he...

    31. FT Alphaville

      October 26, 2011

      Snap news

      Breaking pre-market news on Wednesday, - Lehman’s joint chapter 11 plan gets support from creditors holding over $160bn in...

    32. July 31, 2011

      Inventories: the bullwhip effect

      Producers of almost everything were left stranded when the global downturn took hold and retailers ran down inventories. On...

    33. July 27, 2011

      Merck: writedowns fail to dim prospects

      Investors expect new management to downplay a company’s prospects and write down assets. Frans van Houten, chief executive...

    34. July 27, 2011

      Merck reports operating loss of €11m

      Merck reduced profits guidance for the year as it posted second-quarter losses worse than expectations, driven by...

    35. July 17, 2011

      The job: Corporate orchestra manager

      Stefan Reinhardt, Merck In the 19th century there was an orchestra for Merck employees, which was restarted in Germany in...

    36. May 19, 2011

      Thermo Fisher to pay €2.47bn for Phadia

      Thermo Fisher, the US medical equipment company, has agreed to buy Phadia, an allergy diagnosis company, from private equity...

    37. May 19, 2011

      US and Europe escape worst of quake’s aftershock

      US and European companies have generally suffered only minor and short-lived disruption as a result of the March 11...

    38. March 28, 2011

      Actelion fights back over Elliott campaign

      Actelion, the Swiss biotech group being stalked by Elliott Advisors on Monday accused the leading hedge fund of lacking a...

    Search for Merck KGaA and